Secondary Stock OfferingsBy The Online Investor Staff, updated Thu., Feb. 27, 2:50 PM
|This Slide: #24 of 25|
Slide #24. Xeris Pharmaceuticals, Inc. — Secondary Offering
Xeris Pharmaceuticals, Inc. (NASDAQ:XERS)
Date of Pricing:
Price Per Share:
Secondary Offering Details:
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All shares of common stock will be offered by Xeris. Xeris expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 2/11- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a public offering price of $4.15 per share, before underwriting discounts and commissions and other offering expenses, for gross proceeds of approximately $37.4 million. All shares of common stock will be offered by Xeris. The Company has also granted the underwriters a 30-day option to purchase from the Company up to an additional 1,350,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on February 14, 2020, subject to customary closing conditions.
Xeris Pharmaceuticals is a specialty pharmaceutical company, utilizing its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize injectable and infusible drug formulations. Co.'s primary product candidate, Gvoke HypoPen, delivers glucagon via a commercially-available auto-injector for the treatment of severe hypoglycemia, a potentially life-threatening condition, in people with diabetes. In addition, Co. is applying its technology platforms to convert other commercially-available drugs into room-temperature stable liquid formulations to address the needs in multiple therapeutic areas and conditions, including epilepsy and diabetes.
XERS SEC Filing Email Alerts Service
Open the XERS Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 79% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite